This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
by Zacks Equity Research
Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.
Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?
by Zacks Equity Research
Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
by Zacks Equity Research
Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
by Zacks Equity Research
Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
by Zacks Equity Research
Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 50.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
Best Momentum Stocks to Buy for January 3rd
by Zacks Equity Research
SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
New Strong Buy Stocks for January 3rd
by Zacks Equity Research
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
by Sundeep Ganoria
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 82.6% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
by Zacks Equity Research
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
by Zacks Equity Research
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
by Zacks Equity Research
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.